![]() | Only 14 pages are availabe for public view |
Abstract Introduction: DLBC-NHL is the most common lymphoid neoplasm and constitutes almost 50% of all NHLs. Methods: This thesis includes 485 patients was conducted to study the outcomes in patients with DLBC-NHL among patients treated at Tanta Cancer Center (TCC) between 2003 and 2006 and followed up till March 2014. Results: 88% of patients received CTx being CHOP in 72.4% of cases. CR was achieved in 62.1%, PFS was 21.4 months. The median OS was 20 months. Conclusions: Outcomes of DBLC-NHL at TCC is comparable to those in the literature. Adding Rituximab is recommended to further improve the treatment |